HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced the signing of a non-binding term sheet with a global medical device manufacturer for a strategic investment. This investment contemplates $2.5 million to purchase Series A Convertible Preferred Stock at a $50 million pre-money valuation.
The terms of the Series A Preferred Stock are expected to include a dividend based on current market conditions and the right to appoint a director to HOPE's Board. The pre-money valuation will be subject to future adjustment based on actual Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the third quarter ended September 30, 2026.
This investment, combined with expected bank financing and current balance sheet assets, is anticipated to close concurrently with and in support of HOPE's recently announced clinic acquisitions. This strategic partnership aligns with HOPE's vision of providing comprehensive interventional psychiatry treatments globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.